Product
LUCAR-G39D
1 clinical trial
2 indications
Indication
B-Cell Non-Hodgkin Lymphoma RecurrentIndication
B-cell non-Hodgkin lymphoma-refractoryClinical trial
A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LUCAR-G39D, a Dual-targeted Cell Preparation Targeting CD19/CD20, in Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2026-06-30